038.F NovoCure Limited

Healthcare Medical Devices Frankfurt Exchange
10.31 EUR
Close of Nov 11, 2026
8.12 17.24
Market cap
EUR 1.21B
P/E
-
P/B
4.13x
ROE
-37.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 038.F undervalued?

Graham number

The Graham number of NovoCure Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NovoCure Limited fundamental analysis

No fundamental analysis for NovoCure Limited yet.

NovoCure Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NovoCure Limited

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-smal…

Full company profile